Fujifilm to Invest $200 Million to Expand Cell Therapy Development, Manufacturing Capabilities
By Ronnie Harui
Fujifilm plans to invest $200 million in two subsidiaries in the U.S. to expand its global cell therapy contract development and manufacturing capabilities, the Japanese conglomerate said Tuesday.
The investment is earmarked for the new headquarters of Fujifilm Cellular Dynamics in Wisconsin and the California site of Fujifilm Diosynth Biotechnologies, Fujifilm said in a statement. The investment will enable Fujifilm to support the expanding cell therapy market, which is expected to grow by more than 30% a year from an estimated $3.3 billion in fiscal 2022, it added.
Cell therapies are a promising treatment with the ability to augment, repair and replace human biology, including organs, tissues and cells, Fujifilm said.
Write to Ronnie Harui at ronnie.harui@wsj.com
(END) Dow Jones Newswires
December 04, 2023 23:14 ET (04:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing